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Abstract Objective: To deter-
mine the diagnostic performance of
a Bayesian Decision-Support System
(BDSS) for ventilator-associated
pneumonia (VAP). Design: A previ-
ously developed BDSS, automatically
obtaining patient data from pa-
tient information systems, provides
likelihood predictions of VAP. In
a prospectively studied cohort of 872
ICU patients, VAP was diagnosed
by two infectious-disease specialists
using a decision tree (reference diag-
nosis). After internal validation daily
BDSS predictions were compared
with the reference diagnosis. For
data analysis two approaches were
pursued: using BDSS predictions
(a) for all 9422 patient days, and (b)
only for the 238 days with presumed
respiratory tract infections (RTI) ac-
cording to the responsible physicians.
Measurements and results: 157 (66%)
of 238 days with presumed RTI ful-
filled criteria for VAP. In approach (a),
median daily BDSS likelihood pre-
dictions for days with and without
VAP were 77% [Interquartile range
(IQR) = 56–91%] and 14% [IQR
5–42%, p < 0.001, Mann–Whitney
U-test (MWU)], respectively. In
receiver operating characteristics
(ROC) analysis, optimal BDSS cut-
off point for VAP was 46%, and with
this cut-off point positive predictive
value (PPV) and negative predictive
value (NPV) were 6.1 and 99.6%,
respectively [AUC = 0.857 (95%
CI 0.827–0.888)]. In approach (b),
optimal cut-off for VAP was 78%,
and with this cut-off point PPV and
NPV were 86 and 66%, respectively
[AUC = 0.846 (95% CI 0.794–0.899)].
Conclusions: As compared with the
reference diagnosis, the BDSS had
good test characteristics for diagnos-
ing VAP, and might become a useful
tool for assisting ICU physicians,
both for routinely daily assessment
and in patients clinically suspected of
having VAP. Empirical validation of
its performance is now warranted.
Keywords Ventilator-associated
pneumonia · Decision-support
system · Bayesian network
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Introduction
Ventilator-associated pneumonia (VAP) is the most
frequently occurring nosocomial infection among me-
chanically ventilated patients in intensive care units
(ICUs). Reported incidence rates of VAP have ranged
from 5 to 67%, depending on the selection of patients and
the criteria used to establish its diagnosis [1].
In the absence of a clinically available gold standard,
VAP is usually diagnosed according to a combination of
criteria, such as systemic signs of infection, abnormali-
ties on chest radiograph, and microbiological identifica-
tion of pathogens; however, each of these criterion com-
bines high sensitivity with low specificity. In an attempt
to raise diagnostic accuracy, algorithms, such as the Cen-
ters for Disease Control definition for nosocomial pneu-
monia, and the Clinical Pulmonary Infection Score (CPIS),
have been developed [2, 3]. Furthermore, invasive diagnos-
tic techniques, such as bronchoalveolar lavage (BAL) and
protected specimen brush (PSB), and quantitative analysis
of microbiological cultures, have been proposed to better
distinguish between colonization and infection of the res-
piratory tract [4–6]. Nevertheless, bronchoscopy includes
a certain, though probably small, risk for complications
and quantitative culturing is expensive and labor intensive.
As a result, these techniques have not yet become common
practice in most ICUs.
Presently, patient records have become fully com-
puterized and linked to hospital information systems in
many ICUs. These systems contain all relevant variables
on which intensive care physicians base their clinical
decision. In such a setting, computerized decision-support
systems may assist in diagnosing VAP. For these purposes,
a Bayesian approach seems most attractive, because these
models are able to deal with uncertainties, such as missing
values, can be improved by “self-learning,” and can be
linked to computerized patient record systems [7]. We
developed such a Bayesian Decision-Support System
(BDSS) for diagnosing VAP [8]. The aim of the present
study was to compare the diagnostic properties of the
BDSS with a reference diagnosis in two cohorts of mech-
anically ventilated patients. Firstly, in 872 consecutively
admitted patients (and on each day of ventilation), and sec-
ondly, in a nested subgroup of 238 patients with a clinical
suspicion of VAP (on the day of clinical suspicion only).
Materials and methods
Setting
All patients admitted to two ICUs (a ten-bed medical ICU
and an eight-bed neurosurgical ICU) of the University
Medical Center Utrecht (UMCU) between 1 January 2000
and 1 January 2003 were included in this prospective
cohort study. The UMCU is a 1062-bed tertiary care
hospital. As both ICUs are equipped with patient data
management systems, all relevant clinical, laboratory, and
microbiological variables are registered on a daily basis.
Indications for antibiotic use, as judged by the attending
physicians, and interpretation of chest radiographs by
radiologists were manually added to the database. Patients
receiving home mechanical ventilation were excluded.
As no intervention was evaluated and daily care was not
influenced by the study, the institutional review board
waived the necessity of informed consent.
Bayesian decision-support system
A Bayesian network (BN) is a graphical representation of
a process (in our case VAP) involving a set of variables
based on probability theory. A BN consists of nodes rep-
resenting variables (containing tables with probabilities)
and arrows, where the direction of an arrow indicates
the relationship between the parent node and the child
node. The qualitative part of a relationship between nodes
is characterized by conditional probabilities. For each
variable in the BN there exists an a priori probability
distribution, representing what is known about a vari-
able without any evidence. When there is evidence, for
example clinical signs, the a posteriori distribution can
be calculated based on these clinical signs. Bayesian
networks are often used in fields where decision-making
occurs under uncertainty, such as in healthcare. The BDSS
for diagnosing VAP incorporates (conditional) probability
distributions that were initially assessed subjectively,
that is, either estimated (by C.A.M.S. and M.J.M.B.)
or obtained from scientific literature. Fig. 1a shows the
global structure of the model. Subsequently, the estimated
probabilities (being the qualitative part of the model)
were updated where needed using machine learning
techniques [9]. This learning process was performed as
follows:
1. A randomly selected subset (50% of the cases) of the
data was used for learning the probability distributions
on the basis of the models’ original estimated probabil-
ities.
2. The diagnostic performance of the new model was as-
sessed by testing it on the remainder number of cases,
i.e., the other half of the data set, and calculating the
area under the receiver operating characteristics (ROC)
curve.
This process was repeated ten times to rule out chance
and to prevent for overfitting. The performance (measured
in area under the ROC curve) of all ten potential mod-
els were compared, and the model with the median per-
formance was considered our new model. (The results of
these internal learning steps are not presented but are avail-
able upon request.)
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Fig. 1 a Representation of the global architecture of the BDSS for
VAP. b Diagnostic part of the BDSS for VAP in detail. (See ESM for
additional information)
The diagnostic part (shown in detail in Fig. 1b) of the
BDSS uses the variables body temperature, antipyretic
drugs, blood leukocyte count, infiltrative abnormalities on
chest X-ray (radiological signs), PaO2/FiO2 ratio, sputum
production, sputum color, and duration of mechanical ven-
tilation. The definitions of these variables are summarized
in Table 1. One of the advantages of a Bayesian network is
that, unlike other statistical models, such as, for example,
logistic regression, it can handle missing values in such
a way that when, for example, a patient’s body temperature
is unknown, still the posterior probability of having VAP
can be calculated. On the basis of these variables and
probability distributions, the BDSS calculates the likeli-
hood, i.e., the posterior probability, of having VAP that
ranges from 0 to 100%. With the exception of information
regarding chest radiographs and tracheal aspirate cultures,
which had to be added manually, all information required
for the BDSS network was automatically retrieved from
patient information systems.
Reference definition of VAP
In the absence of a gold standard for diagnosing VAP, a di-
agnostic decision tree was developed to categorize all clini-
cally suspected episodes of VAP (Fig. 2). In this diagnostic
decision tree aspects of different proposed diagnostic algo-
rithms were combined [2, 3, 11]. Categorization was per-
formed through independent adjudication by two reviewers
(C.A.M.S. and M.J.M.B.) taking all relevant clinical, mi-
crobiological, and radiological criteria. Episodes of clini-
cal suspicion of VAP (defined as days on which clinicians
had prescribed antibiotics for presumed respiratory infec-
tions or infections without evident focus) were evaluated
at the time of clinical suspicion as well as in the subse-
quent 3 days. Disagreement in categorization between both
reviewers was resolved through discussion and consensus
was achieved on all cases.
On the day of prescription of antibiotics fulfillment of
criteria of clinical suspicion was determined (Fig. 2). The
criteria of possible VAP, probable VAP, definite VAP, or
definite absence of VAP were verified at day 3 in all pa-
tients with clinical suspicion of VAP. All episodes with
“clinical suspicion,” as well as “possible,” “probable,” and
“definite” VAP were considered VAP. All analyses were
performed for the categories “VAP” vs. “non-VAP,” as well
as for the different categories of severity of VAP (“clinical
suspicion,” “possible,” “probable,” and “definite” VAP vs.
non-VAP).
Statistical analysis
For data analysis two approaches were pursued. Test
characteristics of the BDSS were determined for a situa-
tion in which all “VAP positive” and all “VAP negative”
patient days (n = 9422) were included, as well as for the
situation in which only the days that antibiotics were
prescribed because of presumed respiratory tract infection
(n = 238) were included. In the latter analysis, VAP
diagnosis was confirmed, according to our reference test,
in 157 days.
Daily predictions of the likelihood of VAP by the
BDSS were retrospectively compared with the reference
diagnosis of VAP. Data were expressed as absolute
numbers with percentages and as means or medians
with standard deviation or range. Subsequently, since
VAP is considered a sub-acutely developing disease [12,
13], BDSS’ predictions around the time of diagnosis
for patients diagnosed with VAP were compared with
BDSS’ predictions for control patients not diagnosed with
VAP during their stay in ICU. Controls were matched on
gender, ICU ward, and number of mechanically ventilated
days at the time of analysis.
Independent variables were compared by Mann–Whit-
ney U-test or t-test, when appropriate, and Wilcoxon
signed-rank test was used for non-independent variables.
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Table 1 Definitions of variables used in the Bayesian Decision-Support System. Each variable relates to the period within 24 h before time
of ventilator-associated pneumonia likelihood prediction
Variable Values Classifications Details
Body temperature < 36.0 or > 38.5◦C Abnormal
Other Normal
Sputum production [3] ≥ 14 points Abnormal Scoring points of sputum
production per ICU day:
none = +0; little = +1;
moderate = +2; much = +3
Other Normal
Sputum color [10] Yellow or green Purulent
Other Non-purulent
PaO2/FiO2 ratio ≤ 205 mmHg or absolute decrease Abnormal
of > 35 mmHg compared with
the preceding day
Other Normal
Antipyretic drugs acetaminophen or non-steroid Yes
anti-inflammatory drugs, steroids
Other No
Chest X-ray Localized or diffuse infiltrate Abnormal
Other Normal
Blood leukocyte count < 4 × 109/l Abnormal
or > 11 × 109/l
otherwise Normal
Mechanical ventilation 0–48 h 0–48 h Excluded
48–96 h 48–96 h
96–144 h 96–144 h
> 144 h > 144 h
No. of admissions 909
No. of patients 872
No. of patient days 9422
Age (years; mean ± SD) 54 ± 18
Male gender (n, %) 507 (58)
APACHE (mean ± SD) n = 752
24 ± 7
ICU mortality (%) 25.9
Day of admission ICU (mean ± SD), median (range in days) 13.5 ± 14, 8.6 (2–109)













Table 2 Patient characteristics
A p-value less than 0.05 was considered statistically sig-
nificant. Test characteristics of the BDSS were analyzed
using ROC curves and by calculation of the likelihood
ratio (LR) [14]. The SPSS statistical software (version 12,
SPSS, Chicago, Ill.) for Windows was used to perform
these analyses.
Hugin Professional software (http://www.hugin.com)
was used to construct the Bayesian network model and to
calculate all probabilities needed for our analyses.
Results
In all, 872 patients (909 admissions) were included with
a total of 9422 patient days (Table 2). Antibiotics were
prescribed for presumed respiratory tract infection on
day 238 (Fig. 2). Based on the diagnostic decision tree,
157 episodes (66%) of VAP were diagnosed, subdivided
into “clinical suspicion only” (n = 58), “possible” (n = 78),
and “probable” (n = 21). There were no cases of definite
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Fig. 2 Decision tree for diagnosing VAP: number of episodes of
presumed respiratory tract infections (RTI) and number of episodes
according to the definitions of VAP. (See ESM for additional infor-
mation)
VAP. The overall incidence of VAP was 18% with an
average incidence per patient-day of 1.7%.
The BDSS correctly identified the days that VAP was
diagnosed. Median likelihood prediction of VAP for these
157 days was 77% [Interquartile range (IQR) = 56–91%],
Fig. 3 Box plots for the different
definitions of VAP. Statistical
significant differences were
determined between median
predictions for Only clinical
suspicion and Possible VAP
(p < 0.05), and between Only
clinical suspicion and Probable
VAP (p = 0.05). (See ESM for
additional information)
as compared with 14% [IQR 5–42%] for the 9265 days
with absence of VAP (p < 0.001). Median likelihood pre-
dictions were 72% [IQR 39–90%] for “clinical suspicion
only,” 89% [IQR 66–92%] for “possible,” and 88% [IQR
47–96%] for “probable” VAP (Fig. 3).
In the days before VAP diagnosis, median BDSS pos-
terior probabilities increased from 28% on day –3, to 35%
on day –2 and day –1, to 77% on the day of VAP. In con-
trast, only small changes in posterior probabilities were ob-
served in control patients (median values ranging from 16
to 20%) during the three successive days. After diagnosing
VAP, median posterior probabilities decreased from 77 to
30% on day +1, 28% on day +2, and 29% on day +3.
The ROC curve for BDSS predictions and VAP (yes
or no, 157 episodes) had an area under the curve (AUC)
of 0.857 [95% CI 0.827–0.888], with an optimal cut-off
point (optimal trade-off between sensitivity and specificity,
as identified by SPSS) for diagnosing VAP of 46% (i.e.,
a prediction > 46% would be considered VAP). This cut-
off point had a sensitivity and specificity of 80%, with
a positive predictive value (PPV) of 6.1% and a negative
predictive value (NPV) of 99.6%. For this cut-off point
the likelihood ratio for a positive test (LR+) was 4.0. The
AUC was somewhat higher for episodes fulfilling criteria
of “possible” [AUC = 0.884 (95% CI 0.842–0.925, opti-
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mal cut-off = 52.6%)] and “probable” VAP [AUC = 0.875
(95% CI 0.804–0.945, optimal cut-off = 53.0%)], respec-
tively. For episodes fulfilling criteria of “clinical suspicion
only” the AUC was 0.818 (95% CI 0.765–0.871), with an
optimal cut-off point of 40.6%.
In the second approach, the diagnostic performance of
the BDSS was evaluated in the cohort of 238 patient-days
on which antibiotics were prescribed for presumed respira-
tory tract infection (of which 157 episodes were considered
VAP). Here, the optimal cut-off point for VAP was 78%,
with sensitivity and specificity of 79%, PPV of 87%, and
NPV of 66%. In this analysis the AUC was 0.846 (95%
CI 0.794–0.899), which hardly changed when using only
episodes of “possible” [0.853 (95% CI 0.791–0.916 95%
CI)] or “probable” VAP [0.875 (95% CI 0.804–0.945)].
The LR for a positive test in this approach was 3.8.
Discussion
A Bayesian Decision-Support System, linked to comput-
erized patient record systems in the ICU, accurately pre-
dicted absence and presence of VAP. Two approaches for
application were analyzed. When used on a daily basis,
BDSS predictions had extremely high negative predictive
values, but low positive predictive values. When restricted
to the days that physicians prescribed antibiotics for pre-
sumed respiratory tract infections, BDSS predictions had
excellent test characteristics and a positive predictive value
of 87%. Computerized decision-support systems might be-
come accurate, relatively cheap, patient friendly, and safe
adjuncts for intensive care medicine.
The goal of this study was to determine the diagnostic
performance of the BDSS when compared with a reference
diagnosis. For a more detailed introduction to Bayesians
networks, a detailed description of the full model and an
example of computing posterior probabilities given evi-
dence, we refer to previously published work [7, 8]. Nei-
ther did we aim to compare classification performance of
the BDSS with other statistical methods or to determine
the impact of the BDSS on clinical practice; for the latter,
a randomized trial comparing two diagnostic strategies for
relevant outcome parameters is warranted.
The construction of our model has been based, as
much as possible, on the available scientific evidence on
the pathophysiology of VAP, and the conditional prob-
abilities were subsequently tuned by machine learning
techniques. Duration of exposure (ICU stay and mechan-
ical ventilation) and colonization of the upper respiratory
tract were considered the most important risk factors
for VAP [15, 16]. In contrast, gastric colonization and
contamination of ventilatory circuits were not included
in the model, as there is cumulating evidence that gastric
colonization is less relevant than colonization of the upper
respiratory tract [17, 18] and that frequently changing
ventilatory circuits, in attempt to minimize the risks of
contaminated equipment, has not been demonstrated to
prevent VAP [19].
To the best of our knowledge, other BDSSs to diag-
nose VAP have not been described or evaluated before;
however, other approaches for decision-making have
previously been described. A well-known approach is
the Clinical Pulmonary Infection Score (CPIS), proposed
by Pugin et al. [3], taking into account the same clinical
signs and symptoms as the BDSS described in this paper;
however, one major difference between the CPIS score
and our BDSS is the possibility for likelihood prediction
with missing data. Moreover, the approach as proposed
by Singh et al [20] includes reevaluation of the clinical
situation at day 3, after all patients have started with
antibiotics at day 1.
Previously described BDSSs for infectious diseases
other than VAP considered choosing empirical therapy
for bacterial infections [21], predicting the pathogens of
bacteraemia originating from the urinary tract and from
other sites [22–24], and diagnosing community-acquired
pneumonia (CAP) [25]. This BDSS for diagnosing CAP
was retrospectively evaluated in 41,371 patients that
had visited an emergency department and for which
a discharge diagnosis was known. Five hundred fifty-three
patients were diagnosed with CAP. The BDSS had a sen-
sitivity for diagnosing CAP of 95%, with a specificity
of 96.5%, an area under the ROC curve of 0.98, and
a positive predictive value of 26.8%. This model is now
being used in the emergency room to identify patients with
CAP [26], but prospective data on performance, effects
on patient care, and outcome or cost-benefit analyses have
not been reported to date.
The development and evaluation of our BDSS deserves
some comments and one important limitation must be dis-
cussed. As all diagnostic studies for VAP, this study suf-
fers from the absence of an available gold standard. An
attractive alternative for the only true gold standard (i.e.,
histology) would be bronchoscopy with quantitative cul-
tures. Yet, as this procedure was not common practice in
our ICU, it could not be used for all patients; therefore,
we defined a decision tree (Fig. 2) and prospectively cat-
egorized all patients with a clinical suspicion of VAP ac-
cording to this scheme. It is noteworthy that this was per-
formed before the BDSS model was used for calculation of
likelihood predictions for VAP. Still, this does not exclude
the possibility of misclassification. Another potential in-
sufficiency is that we only included the days of initiation
of antibiotic prescription for presumed respiratory tract in-
fection or for infection without obvious focus in the deci-
sion tree. In this way we could have missed cases of VAP
that were not treated with antibiotics. Yet, it is generally
assumed that unnecessary treatment of presumed VAP oc-
curs much more frequently than unnecessarily withholding
treatment in patients with true VAP; therefore, our defini-
tion of patient inclusion probably had a high sensitivity to
capture all episodes of true VAP. Nevertheless, in the ab-
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sence of a gold standard, a prospective randomized trial is
needed to determine the clinical benefits, expressed in pa-
tient outcome, antibiotic use, and costs of a new diagnostic
test.
When used on a daily basis, BDSS predictions had
a PPV of 6.1%, which might seem low. Yet, with an
overall incidence of 18% and average daily risk of 1.7%,
a diagnostic test with sensitivity and specificity of 95%
would still have a PPV of only 25%; therefore, even good
diagnostic tests can have poor PPV in low-prevalence
settings [27]. The incidence rates as observed in our
study are fully comparable to incidences reported in
other studies [1, 15], and this problem, therefore, seems
unavoidable when using a diagnostic test in daily practice.
The use of a BDSS in the daily assessment of patients
might lead physicians to withhold antibiotics on days that
the likelihood for VAP is low, and could thus be helpful
in reducing unnecessary antibiotic use. The problem of
low PPV is avoided when restricting the diagnostic test to
those days on which the physician has a clinical suspicion
of VAP. In such an approach BDSS predictions had
excellent test characteristics (AUC = 0.846), but, again, as
compared with our reference standard.
The specificity of the BDSS for VAP was high, but not
100%. There are several explanations for false-positive test
results. Because of the complex disease presentations in
critically ill patients, there is always the possibility of other
infections, also associated with systemic signs of infec-
tion. In our cohort, though, a comparison of the days with
clinical suspicions of VAP with all other days on which
no antibiotics were prescribed, reflecting absence of clin-
ical suspicion of any infection, revealed similar sensitiv-
ity and specificity (data not given here). Another potential
diagnostic problem is the sub-acute development of VAP,
which may lead to false-positive predictions around the
time of diagnosis. We therefore investigated whether pa-
tients developing VAP already had higher prediction like-
lihoods in the days before diagnosis, in a matched-cohort
analysis. Indeed, in the days before VAP was diagnosed,
median BDSS posterior probabilities increased from the
days before VAP until the day VAP was diagnosed.
Conclusion
We have presented the first attempt to use a fully auto-
mated Bayesian Decision-Support System for diagnosing
and ruling out VAP. In two approaches (using it on a daily
basis for all patients or only in cases of clinical suspicion
of VAP) the system performed reasonably well. The next
steps will be incorporation of pathogen prediction and an-
timicrobial therapy advice. The diagnostic properties of
this model should be investigated further in other ICU pop-
ulations and, preferably, compared with usual care in a ran-
domized study design.
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